ADD Forums - Attention Deficit Hyperactivity Disorder Support and Information Resources Community  

Go Back   ADD Forums - Attention Deficit Hyperactivity Disorder Support and Information Resources Community > SCIENTIFIC DISCUSSIONS, RESEARCH, NEWS AND EVENTS > Current ADD Events & News > ADD News
Register Blogs FAQ Chat Members List Calendar Donate Gallery Arcade Mark Forums Read

ADD News News from around the world about ADD/ADHD, other disorders, and some rather bizzarre & strange stories.

Thread Tools Display Modes
Old 10-27-04, 04:37 PM
Andi's Avatar
Andi Andi is offline

Join Date: Mar 2003
Location: ?
Posts: 5,046
Blog Entries: 1
Thanks: 1,605
Thanked 8,240 Times in 2,593 Posts
Andi has a reputation beyond reputeAndi has a reputation beyond reputeAndi has a reputation beyond reputeAndi has a reputation beyond reputeAndi has a reputation beyond reputeAndi has a reputation beyond reputeAndi has a reputation beyond reputeAndi has a reputation beyond reputeAndi has a reputation beyond reputeAndi has a reputation beyond reputeAndi has a reputation beyond repute
Datamonitor: ADHD Children Not Coming to Attention of Parents and Teachers

LONDON, Oct. 21, 2004--School can be a difficult place at the best of times, however for the more than 20 million children** that suffer from attention deficit and hyperactivity disorder (ADHD) it can be especially troubling, moreso as only 12% of children suffering from ADHD are ever correctly diagnosed. On top of that, a new report by independent market analyst Datamonitor* reveals that many patients aren’t receiving the best available treatment because physicians are sticking with older immediate release, short duration drugs rather than a number of newer long-acting therapies that are on the market.

Hugely undiagnosed

Datamonitor estimates that 23 million children and adolescents across the seven major pharmaceutical markets** suffer from ADHD, a physician perceived prevalence rate of about 15%. However currently only 12% of those, or only 1.8% of children in the total population are actually correctly diagnosed with ADHD, says Datamonitor central nervous system analyst Alistair Sinclair.

“Although these figures are higher than those previously reported, they do indicate that a huge proportion of patients remain undiagnosed and therefore untreated.”

Although societal and clinical awareness of ADHD is ever growing, Sinclair says there are still significant gaps between knowledge, recognition and referral of the disease at all points of the diagnostic chain.

“What is known is that ADHD is a heterogeneous disorder, with no known etiology and that it appears to be slightly more prevalent in adolescents than children. However, recent research is starting to piece together the primary contributing factors including structural abnormalities, genetic predisposition and neurotransmitter dysfunction.”

The two most widely used classification systems defining hyperactivity disorders are the American Psychiatric Association’s (APA) Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV), and the International Classification of Disease of the World Health Organization (ICD-10), which classify the disorders as ADHD and hyperkinetic disorders (HKD), respectively, Sinclair says.

“The DSM-IV lists 18 symptoms of ADHD, which can be divided into three subtypes: predominantly inattentive, predominantly hyperactive-impulsive, and the combined type, in which the patient must fully meet the criteria for both of the other two subtypes. Additionally, symptoms causing clinically significant impairment must be observed in at least two settings, such as school and home, with onset of symptoms before the age of seven, lasting for at least six months.”

Basic symptoms of ADHD classified as inattentive include a failure to attend to details, difficulty in sustaining attention, losing things and avoiding sustained effort. Symptoms considered hyperactive include fidgeting with hands and feet, leaving ones seat in the classroom, running and climbing about and an inability to play quietly, Sinclair says.

“Obviously a child or adolescent suffering from ADHD would find it difficult to achieve in a classroom environment, and therefore risks being left behind its year-group academically and socially. Furthermore, Datamonitor’s research indicates that 43% of physicians perceived that teachers are not aware of ADHD.”

Stimulating recovery

Historically, the stimulants, including methylphenidate- and amphetamine-based drugs have formed the bulk of pharmacological therapy for the treatment of pediatric and adolescent ADHD, Sinclair says. “Stimulants work by enhancing the transmission of catecholamines, by blocking dopamine and noradrenalin reuptake transporters. The resultant effect leads to an increase in attention and decrease in impulsivity.”

However these immediate release, short duration of action drugs usually required a three-times daily dosage regime, which was problematic (especially for schoolchildren) because stimulants are controlled substances. But the refomulation of these drugs as modified release allows for equal efficacy plus the convenience of a once-daily dosage, Sinclair says.

“Second generation stimulants like Metadate CD, Ritalin LA have a duration of action of six to eight hours, while Concerta and Adderall XR have an effect over a 10 to 12 hour period. The convenience of the once-daily dosage also helps remove some of the social stigma associated with ADHD.”

Despite the availability of numerous longer-acting therapies, currently only 20% of newly diagnosed patients receive such drugs as a first-line treatment, falling to 3% at second-line. Immediate-release drugs are often rated superior to their modified release versions, and the convenience of a once-daily dosage strategy is rated as a low priority by physicians, Sinclair says.

“Manufacturers need to promote the benefits of once-daily formulations which provide increased compliance, smoother drug profile and reduced social stigma; features that will significantly improve patient quality of life.”

Ends Notes for editors *DMHC2008 Stakeholder Insight: Attention Deficit Disorder and Hyperactivity Disorder -Prescriber Attention Still Held by Short Acting Stimulant Drugs

**Seven major pharmaceutical markets; USA, UK, Italy, Spain, Germany, France and Japan.

In the US, ADHD has a prevalence of 10.7%, with 8.70 million sufferers, however only 18.5% of those, or 1.62 million are actually diagnosed.

In the UK, ADHD has a prevalence of 16.9% with 2.50 million sufferers, however only 6.1% of those, or 0.15 million are actually diagnosed
Be nice to me, I have powers and Andrew no longer compensates me with shoes!!
Do what you feel in your heart to be right - for you'll be criticized anyway. You'll be damned if you do, and damned if you don't.--Eleanor Roosevelt
I'm all in favor of keeping dangerous weapons out of the hands of fools. Let's start with typewriters. --Frank Lloyd Wright

Everything I write is fully substantiated by my personal opinion.
Reply With Quote


Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)
Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On
Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
Coincidence of ADHD and Creativity Nova General ADD Talk 44 10-25-16 01:55 AM
Controversial Treatments for Children With Attention-Deficit/Hyperactivity Disorder scuro Children's Diagnosis & Treatment 74 09-25-14 11:22 AM
ADHD and Children Who Are Gifted Nova General ADD Talk 21 03-20-11 07:28 PM
Mild Autism in Adults speedo Aspergers/Autism Spectrum/PDD 27 05-30-08 06:26 PM
Note on the DSM-IV and Diagnosis Trooper Keith Adult Diagnosis & Treatment 44 02-07-06 08:00 PM

All times are GMT -4. The time now is 06:41 AM.

Powered by vBulletin® Version 3.7.4
Copyright ©2000 - 2020, Jelsoft Enterprises Ltd.
(c) 2003 - 2015 ADD Forums